GLP-1s tested for uses beyond weight loss, diabetes
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images Think a …
Altimmune Inc
Eli Lilly, drugmakers show off weight loss drug data
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should …
Amgen could threaten Novo Nordisk, Eli Lilly weight loss drug dominance
The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk and Eli Lilly have …
Altimmune weight loss drug minimized muscle mass loss in trial
Daniel Grill | Tetra Images | Getty Images Altimmune on Wednesday said its experimental drug helped patients shed weight but also minimized the loss of muscle mass in a midstage …
Viking stock doubled Tuesday. Here’s where the next moves in the obesity space could come from
Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but given the vast and valuable market, rivals are still eager to join the race. Bank …
2024 expectations for Wegovy, Ozempic, Zepbound
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed …
Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to …
Stocks making the biggest moves midday: TSLA, DIS, BABA, ULTA
Check out the companies making headlines in midday trading. Tesla — Tesla shares slipped less than 1% as Wall Street assessed the company’s long-anticipated Cybertruck following a delivery launch event …
Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don’t expect this duopoly to end soon, analysts say. But other companies — both big and small — …